Publications by authors named "Maria Beconi"

Claim this Profile
C
Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated Neurodegeneration.
Giulio Auciello, Annalise Di Marco, Odalys Gonzalez Paz, Savina Malancona, Steven Harper, Maria Beconi

J Med Chem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis Model.
Maolin Yu, Mark W Ledeboer, Matthew Daniels, Goran Malojcic, Thomas T Tibbitts, Maria Beconi

ACS Med Chem Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models.
Daniel Elbaum, Maria G Beconi, Edith Monteagudo, Annalise Di Marco, Maria S Quinton

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of acetyl coenzyme A in human whole blood by ultra-performance liquid chromatography-mass spectrometry.
Roberto Speziale, Camilla Montesano, Maria Lucia De Leonibus, Fabio Bonelli, Paola Fezzardi, Maria G Beconi

J Chromatogr B Analyt Technol Biomed Life Sci· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN.
Yiolanda-Panayiota Christou, George A Tanteles, Elena Kkolou, Annita Ormiston, Kostas Konstantopoulos, Maria Beconi

Case Rep Neurol Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis).
Jane S Sutcliffe, Vahri Beaumont, James M Watson, Chang Sing Chew, Maria Beconi

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
John Wityak, Kevin F McGee, Michael P Conlon, Ren Hua Song, Bryan C Duffy, Maria Beconi

J Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.
Laura Orsatti, Roberto Speziale, Maria Vittoria Orsale, Fulvia Caretti, Maria Veneziano, Maria Beconi

J Pharm Biomed Anal· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Leticia M Toledo-Sherman, Michael E Prime, Ladislav Mrzljak, Maria G Beconi, Alan Beresford

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice.
Petr Vodicka, Junghyun Lim, Dana T Williams, Kimberly B Kegel, Kathryn Chase, Maria Beconi

J Huntingtons Dis· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease.
Vahri Beaumont, Larry Park, Arash Rassoulpour, Ulrike Dijkman, Taneli Heikkinen, Maria G Beconi

PLoS Curr· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Roland W Bürli, Christopher A Luckhurst, Omar Aziz, Kim L Matthews, Dawn Yates, Maria Beconi

J Med Chem· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
Dirk Winkler, Maria Beconi, Leticia M Toledo-Sherman, Michael Prime, Andreas Ebneth

J Biomol Screen· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
Maria Beconi, Omar Aziz, Kim Matthews, Lara Moumné, Catherine O'Connell

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048.
Maria G Beconi, Dawn Yates, Kathryn Lyons, Kim Matthews, Steve Clifton

Drug Metab Dispos· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.
John Wityak, Michael E Prime, Frederick A Brookfield, Stephen M Courtney, Sayeh Erfan, Maria Beconi

ACS Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.
Michael E Prime, Frederick A Brookfield, Stephen M Courtney, Simon Gaines, Richard W Marston, Maria Beconi

ACS Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
Michael E Prime, Ole A Andersen, John J Barker, Mark A Brooks, Robert K Y Cheng, Maria Beconi

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of memantine in rats and mice.
Maria G Beconi, David Howland, Larry Park, Kathryn Lyons, Joseph Giuliano

PLoS Curr· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents.
Songpo Guo, Yang Song, Qingqing Huang, Hai Yuan, Baojie Wan, Maria G Beconi

J Med Chem· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors.
Scott D Edmondson, Lan Wei, Jinyou Xu, Jackie Shang, Shiyao Xu, Maria G Beconi

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Maria G Beconi, James R Reed, Yohannes Teffera, Yuan-Qing Xia, Christopher J Kochansky

Drug Metab Dispos· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Scott D Edmondson, Anthony Mastracchio, Robert J Mathvink, Jiafang He, Bart Harper, Maria Beconi

J Med Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
George R Lankas, Barbara Leiting, Ranabir Sinha Roy, George J Eiermann, Maria G Beconi

Diabetes· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Dooseop Kim, Liping Wang, Maria Beconi, George J Eiermann, Michael H Fisher

J Med Chem· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis